ISG20: an enigmatic antiviral RNase targeting multiple viruses

Séverine Deymier, Camille Louvat, Francesca Fiorini and Andrea Cimarelli

Keywords
epitranscriptomic modifications; interferon; ISG20; RNase; translational inhibition; virus inhibition

Correspondence
A. Cimarelli, Centre International de Recherche en Infectiologie, 46 Allée d’Italie, Lyon 69007, France
Tel: +33 472728696
E-mail: acimarel@ens-lyon.fr

(AReceived 15 November 2021, revised 31 January 2022, accepted 15 February 2022)
doi:10.1002/2211-5463.13382

Interferon-stimulated gene 20 kDa protein (ISG20) is a relatively understudied antiviral protein capable of inhibiting a broad spectrum of viruses. ISG20 exhibits strong RNase properties, and it belongs to the large family of DEDD exonucleases, present in both prokaryotes and eukaryotes. ISG20 was initially characterized as having strong RNase activity in vitro, suggesting that its inhibitory effects are mediated via direct degradation of viral RNAs. This mechanism of action has since been further elucidated and additional antiviral activities of ISG20 highlighted, including direct degradation of deaminated viral DNA and translational inhibition of viral RNA and nonself RNAs. This review focuses on the current understanding of the main molecular mechanisms of viral inhibition by ISG20 and discusses the latest developments on the features that govern specificity or resistance to its action.

A general canvas for the cellular context of expression of ISG20

ISG20 is an exquisite interferon-regulated protein, and as such, what follows is a very general introduction to interferons (IFNs). The interferon system represents the first line of response against microbial infections [1–3]. During infection, the cell recognizes pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs). Recognition initiates signaling cascades that converge onto several transcription factors (IRF3, IRF7, NF-κB) that migrate in the

Abbreviations
+ssRNA, positive-strand RNA; AEN, apoptosis-enhancing nuclease; APOBEC3A, apolipoprotein B mRNA-editing enzyme catalytic subunit 3A; CB, cajal bodies; cccDNA, covalently closed circular DNA; CHIKV, chikungunya virus; CPV, cricket paralysis virus; DENV, dengue virus; dsRNA/DNA, double-stranded RNA or DNA; E box, enhancer box; eif2, eukaryotic initiation factor 2; eif4, eukaryotic initiation factor 4; eIF4F, eukaryotic initiation factor 4F; Exo, exonuclease motif; HBV, hepatitis B virus; HCV, hepatitis C virus; HEM45, human estrogen-regulated transcript 45 protein; HIV-1, human immunodeficiency virus type 1; I, inosine; IAV, influenza A virus; IFIT1, interferon-tetrapeptide repeat protein 1; IFN, interferon; IFNAR1/2, interferon alpha and beta receptor subunit 1 or 2; IFN-I (IFNa/b), type I interferon; IFN-IL (IFN gamma), type II interferon; IRES, internal ribosome entry site; IRF1/2/3/7/9, interferon regulatory factor 1, 3, 7, or 9; ISG, interferon-stimulated gene; ISG20, interferon-stimulated gene 20kDa protein; ISG20L1, interferon-stimulated exonuclease gene 20kDa-like 1; ISG20L2, interferon-stimulated exonuclease gene 20kDa-like 2; ISRE, interferon-stimulated response element; JAK-STAT, Janus kinase signal transducer and activator of transcription; m1A, N1-methyladenosine; m5C, 5-methylcytosine; m6A, N6-methyladenosine modification; mISG20, mouse ISG20; mTOR, mammalian target of rapamycin; NP, nucleoprotein; NS, nonstructural; P bodies, processing bodies; PAMP, pathogen-associated molecular pattern; pgRNA, pregenomic RNA; Pol(III), polynucleosinic-polycytidylic acid; PRR, pattern recognition receptor; rDNA, relaxed circular DNA; RdRp, RNA-dependent RNA polymerase; RIG-I, retinoic acid-inducible gene I; RNaseL, ribonuclease L (for latent); RT, reverse transcriptase; SARS-CoV, severe acute respiratory syndrome coronavirus; snoRNA, small nuclear RNA; snRNA, small nuclear RNA; Sp-1, specificity protein 1; s-sRNA, negative-strand RNA; s-sRNA/DNA, single-stranded RNA or DNA; STAT1/2, signal transducer and activator of transcription 1 or 2; TLR3, Toll-like receptor 3; UMP, uridine 5’-monophosphate; USF-1, upstream stimulatory factor 1; VEEV, Venezuelan equine encephalitis virus; VSV, vesicular stomatitis virus; WNV, West Nile virus; WT, wild-type; YTHDF2, YTH-domain family 2; ε, epsilon; ψ, pseudouridine.
nucleus and lead to the synthesis of type I interferons (IFN-I; IFNα/β). Contrary to more specialized interferons (i.e., types II and III, which are specific to immune cells), IFN-Is are instrumental to induce a generalized antiviral state and to start innate immune responses.

In humans, the IFN locus on human chromosome 9p contains 13 functional α genes (IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, IFNα13, IFNα14, IFNα16, IFNα17, and IFNα21), one β gene situated syntenically (IFNβ1) [4,5], and three more distantly related IFN genes (IFNε, IFNκ, and IFNω). Members of the IFN family exhibit from 30 to 80% sequence identity, and all are ligands for the cell surface receptors IFNα receptor subunits 1 and 2 (IFNAR1/2). The ligand–receptor interaction leads to the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) signaling pathway and to the upregulation of several hundreds of genes, referred to as interferon-stimulated genes (ISGs). These genes exert numerous effects aimed at blocking the microbe at multiple steps (entry into the cell, RNA processing, translation, etc.) [4–6].

In a very simplified manner then, this innate defense mechanism recognizes common features present in a given class of pathogens (reverse transcription as a blueprint for retroviruses, lipopolysaccharide for bacteria, etc.) in cells that are compromised. Through the rapid diffusion of signals (the IFNs), this leads to a generalized antimicrobial cellular state in which cells become more resistant to infection. This intrinsic cellular resistance is ultimately mediated by interferon-sensitive genes (ISGs) that act at multiple layers to inhibit pathogen replication either by directly targeting it or by indirectly affecting cellular processes normally required for its replication.

If the mechanism of action of some ISGs is well described in the literature, the role of many others remains either unknown or unclear.

Among ISGs that act as antiviral effectors and that are thus thought to inhibit virus infection by directly binding or altering one of their components is the interferon-stimulated gene 20 kDa protein (ISG20), also known as human estrogen-regulated transcript 45 protein (HEM45) [7,8]. ISG20 is the second RNase described to be induced by the IFN system after RNase L [9]. Despite the fact that initial studies reported a simple and direct explanation for viral inhibition by ISG20 (i.e., ISG20 directly degrades viral RNA thanks to its RNase enzymatic properties) [10], the following studies have somewhat complexified our view of how ISG20 may act. The following paragraphs will specifically focus on the discovery of ISG20, on the mechanisms that over the years have been ascribed to ISG20 and to open questions that may help decorticate the antiviral functions of this broad-spectrum antiviral factor.

A historical overview of the discovery of ISG20

ISG20 was discovered in 1997 in Daudi cells as a new interferon-regulated protein [7]. Later studies demonstrated that ISG20 could be induced transcriptionally by both type I (α/β) and type II (γ) IFN through an unique interferon-stimulated response element (ISRE) present in its promoter region, under the control of the IFN regulatory factor 1 (IRF1) [11–13]. Despite being clearly upregulated by IFNs, ISG20 exhibits also variable expression levels at the basal state in several cell types under the control of different transcription factor, as the specificity protein 1 (SP-1) or the upstream stimulatory factor 1 (USF-1), so that ISG20 could have a physiological impact on cellular functions also in the absence of ongoing interferon responses [11]. Independently from the study of Gongora et al, ISG20 was identified as a human estrogen-regulated transcript (HEM45) in breast cancer cell lines [8], hence its double name ISG20/HEM45. Several reports suggest a link between the tumorigenic process and ISG20 [14–17], although the exact mechanism through which ISG20 could influence this process remains unclear [18–20].

In humans, isg20 is located on the chromosome 15q26.1 and codes for a 181 amino acid protein [10,21]. Humans code for two additional proteins bearing high homology with ISG20: the interferon-stimulated exonuclease gene 20 kDa-like 1 and 2 (ISG20L1 and ISG20L2, which share 53 and 48% identity with ISG20, respectively) (Fig. 1A). isg20L1 lays just next to isg20 and has been involved in apoptosis, hence its name of apoptosis-enhancing nuclease (AEN), while isg20L2 is located on chromosome 1q23.1 and has been involved in ribosome biogenesis. At this time, neither ISG20L1 nor ISG20L2 has been reported to possess antiviral activities [22–24].

ISG20, a member of the DnaQ-like (or DDEDD) 3'-5' exonuclease domain superfamily

The DDEDD superfamily of 3'-exonucleases includes a large number of prokaryotic and eukaryotic enzymes that cleave one at a time from the 3'-RNA and/or DNA terminus [25]. Exoribonucleases of this family can be autonomous enzymes or integrated into larger replicative complexes, supporting, for example, the proofreading functions of DNA polymerases, of DNA
repair enzymes, or of RNA maturation and turnover complexes [26]. The architecture of DEDD exonucleases is as conserved as their mechanism of catalysis: The catalytic site is composed of four conserved acidic amino acid residues (Asp-Glu-Asp-Asp) distributed within three exonuclease motifs named ExoI, ExoII, and ExoIII [27,28]. These residues coordinate the two metal ions responsible for the hydrolysis of the last phosphodiester bond of RNA or DNA. Furthermore, the superfamily is subdivided into two major groups, DEDDh and DEDDy, according to the presence of a fifth highly conserved residue within the ExoIII motif, which can be either a histidine (H) or tyrosine (Y) [27] (Fig. 1B). The role of these alternative residues in catalytic activity or substrate binding is still unclear.

ISG20 belongs to the DEDDh subgroup of 3' to 5' exonucleases as a large number of independent RNases such as the ribonuclease T and D, the three prime repair exonuclease 1 (TREX1), or the yeast RNA exonuclease 4 homolog (REX4) (Fig. 1B). Because of the conservation of their basic fold and active site, DEDDh exonucleases have divergent substrate-binding sites due to their different substrate preferences. ISG20 degrades single-stranded RNA (ssRNA) and DNA (ssDNA) in vitro with a strong preference for RNA [10]. The crystal structure of ISG20 complexed with two manganese (Mn) ions and uridine 5'-monophosphate (UMP) has been solved at 1.9 Å resolution [29] (PDB:1WLJ). In this structure, a five-stranded β-sheet core is surrounded by two clusters of α-helices: α3, α4 and α1, α2, α5, α7 (Fig. 1C). Within the active site, the Asp11, Glu13, and Asp154 coordinate MnA, while MnB is coordinated directly by water molecules by

![Fig. 1. ISG20 belongs to the conserved group of DEDDh exonuclease.](image)
Asp94 (Fig. 1C, adapted from Horio et al. [29], PDB:1WLJ). Only the Mn$^{2+}$ showed stimulatory effects on ISG20 activity, whereas other bivalent cations such Mg$^{2+}$, Ca$^{2+}$, or Zn$^{2+}$ did not [10]. Importantly, the conserved His149 interacts with the O2P of the UMP phosphate group, suggesting that this residue cannot be responsible for the preference shown by ISG20 for ssRNA to ssDNA [10,29]. This preference might be exerted by Met14 and Arg53 (Fig. 1C), because they directly interact with the ribose 2'-OH group of the UMP [10,29]. However, deeper mutational analyses or the structure of RNA-bound ISG20 are needed to better understand the molecular bases of ISG20 preference for RNA substrates. Furthermore, concerning the enzymatic mechanism, whether ISG20 acts as a processive or a distributive enzyme has also not been properly investigated so far.

While the purified ISG20, free from any cellular interactor, cleaves essentially ssRNA in vitro, the 3'-structured substrates are likely resistant [10,30]. This resistance has been well characterized in the case of the hepatitis B virus (HBV) RNA encapsidation signal called epsilon (ε) [30,31]. The ε RNA is located near the 5' end of the HBV pregenomic RNA, and it exhibits a long 13-bp basal stem followed by a 6-nt bulge region also called priming loop, a 11-bp upper stem and a terminal hexaloop [32,33] (Fig. 1D). The first full-length structure of HBV ε RNA has been recently solved using solution nuclear magnetic resonance (NMR) spectroscopy [34] (PDB:6VAR; Fig. 1D). This structure is of interest in light of the fact that the specific binding of ISG20 to the HBV ε RNA takes place at the level of the lower stem, in a manner independent of the bulge sequence but dependent of the stem length. More than nine RNA base pairs of ε lower stem seem to be necessary for stable ISG20:ε interaction. Despite this efficient binding, ISG20 was not able to cleave ε RNA substrate [30]. Interestingly, a C-terminal truncated version of ISG20, with the ExoIII motif deleted, has been shown to abolish RNA binding [30]. This suggests that ExoIII could harbor the RNA-binding domain or, alternatively, that the coordination of the Mn by Asp154 is critical for RNA interaction (Fig. 1C).

Recently, a strong exonuclease activity of ISG20 has been reported on deoxyuridine-containing ssDNA. This finding is of interest because deoxyuridine-containing DNA is the result of the editing activity of a second important antiviral factor, the human apolipoprotein B mRNA-editing catalytic polypeptide-like 3A protein (APOBEC3A; in this case, the hepatitis B virus, HBV, and more generally of all members of this family) that deaminates cytosines on viral genomes [35]. This activity is of interest because it connects the concerted action of two antiviral factors in the mutagenesis and degradation of viral genomes, as we will discuss more extensively below.

**Virus inhibition by ISG20**

In light of its exquisite activity against RNA, it is perhaps not surprising, although simplistic, that ISG20 has been described to interfere with the replication of a large spectrum of RNA viruses. This list ranges from negative- or positive-strand RNA viruses such as *Rhabdoviridae* or *Flaviviridae* (for instance, the vesicular stomatitis virus, VSV, or the hepatitis C virus, HCV) to *Retroviridae* such as the human immunodeficiency type 1 virus (HIV-1), the genome of which is reverse-transcribed from a single-stranded RNA to double-stranded DNA [36–39] (for an exhaustive list, Table 1).

From a very schematic manner, negative- and positive-strand RNA viruses undergo an obligatory step of antigenomic RNA synthesis that leads to viral RNA amplification, translation of viral proteins, and ultimately the formation of novel virion particles (as schematically presented in Fig. 2A). The first round of viral translation, which is key to ensure the RNA amplification cycle, occurs either directly from the viral genome in the case of positive-strand RNA viruses or after pioneer transcription in the case of the negative-strand ones. The replication cycle of the viral genome is instead quite distinct in the case of *Retroviridae* and *Hepadnaviridae* that undergo a reverse transcription phase that leads to the formation of linear or circular DNA (Fig. 2B). These nucleic acids are first transported into the nucleus of host cells and then transcribed with the concourse of viral components, similar to cellular genes. In this case therefore, genome amplification is promoted by viral-coded proteins, but is essentially assured by the cellular transcription machinery, and only RNAs of positive polarity are produced during infection [40,41]. Of note, antigenome RNA transcription has been reported for some retroviruses, but the role of these transcripts is either unclear or transcriptional regulation [42,43].

Even through the lenses of this simplified view of their mechanisms of replication, it is difficult to reconcile a single mechanism of inhibition based on the direct degradation of viral RNA against such diverse viruses. Indeed, while most RNA viruses targeted by ISG20 carry out their replication cycle entirely in the cell cytoplasm, some, as *Orthomyxoviridae*, replicate in the nucleus [44–47]. Also replicating away from the
## Table 1. Virus susceptibility to ISG20 inhibition and known modifications of viral RNAs.

| Virus Family | ISG20 inhibition (Refs.) | ISG20 inhibition | 7mG cap (cap 1) Epitranscr. Modif. | Poly(A) tail | Refs. |
|--------------|--------------------------|------------------|----------------------------------|-------------|-------|
| **Negative-polarity RNA viruses** | | | | | |
| **Orthomyxoviridae** | | | | | |
| Influenza A virus (IAV) | Yes; [37,96] | Yes Cap- | m6A | Yes | [97,98] |
| **Peribunyaviridae** | | | | | |
| Bunyamwera (BUNV) | Yes; [80] | Yes Cap- | m6A | Yes | [97,98] |
| Cache Valley virus (CVV) | No; [80] | No; [80] | ND | No | [99,100] |
| Oropouche virus (OROV) | | | | | |
| Schmallenberg virus (SBV) | | | | | |
| Batama virus (BMaV) | | | | | |
| Boraceia virus (BORBV) | | | | | |
| Tacaoiama virus (TCMV) | | | | | |
| Anopheles A virus (ANAV) | | | | | |
| Capim virus (CAPV) | | | | | |
| **Hantaviridae** | | | | | |
| Puumala virus (PUUV) | Yes; [80] | Yes | m6A | Yes | [37,96] |
| **Nairoviridae** | | | | | |
| Dugbe virus (DUGV) | Yes; [80] | Yes | m6A | Yes | [37,96] |
| **Phenuiviridae** | | | | | |
| Rift Valley fever virus (RVFV) | No; [80] | No; [80] | ND | No | [99,100] |
| Severe fever with thrombocytopenia syndrome virus (SFTSV) | | | | | |
| Heartland virus (HRTV) | | | | | |
| **Rhabdoviridae** | Yes; [37,39] | Yes | m6A | Yes | [37,39] |
| Vesicular stomatitis virus (VSV) | Yes; [37,39] | Yes | m6A | Yes | [37,39] |
| **Positive-polarity RNA viruses** | | | | | |
| **Flaviviridae** | | | | | |
| Hepatitis C virus (HCV) | Yes; [24,104,105] | No | m6A, m5C, ψ, m1A, l | No | [89,106–109] |
| Bovine viral diarrhea virus (BVDV) | Yes; [24] | Yes | m6A, m5C, ψ, m1A, l | No | [103–104] |
| West Nile virus (WNV) | Yes; [38] | Yes | m6A (WNV) | m6A, m5C, ψ, m1A, l (DENV) | [89,108,111–115] |
| Dengue virus (DENV) | Yes; [38] | Yes | m6A, m5C, ψ, m1A, l | No | [89,108,111–115] |
| Yellow fever virus (YFV) | Yes; [24,37] | No | m6A, l | m6A, m5C, ψ, m1A | [116–118] |
| Zika virus (ZIKV) | Yes; [24] | Yes | Cap 0* | ND | Yes | [120,121] |
| **Picornaviridae** | Yes; [24,37] | No | Cap 0* | ND | Yes | [120,121] |
| Hepatitis A virus HAV | Yes; [24,37] | No | Cap 0* | ND | Yes | [120,121] |
| Encephalomyocarditis virus (ECMV) | Yes; [24,37] | No | Cap 0* | ND | Yes | [120,121] |
| **Togaviridae** | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Sindbis virus (SINV) | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Chikungunya virus (CHIKV) | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| **Coronaviridae** | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Severe acute respiratory syndrome coronavirus (SARS-CoV-1) | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Severe acute respiratory syndrome coronavirus (SARS-CoV-2) | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Viruses containing retroelements | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| **Retroviridae** | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| Human immunodeficiency virus type 1 (HIV-1) | Yes; [12,119] | Yes | ND | Yes | [120,121] |
| **Hepadnaviridae** | Yes; [24,37] | No | Cap 0* | ND | Yes | [120,121] |
| Hepatitis B virus (HBV) | Yes; [24,37] | No | Cap 0* | ND | Yes | [120,121] |

*Cap 0: m7GpppNp. Di- and trimethylated caps have also been described (m2,7G- and m2,2,7G-caps in the case of SINV). ND, not determined.
cell cytoplasm are Retroviridae and Hepadnaviridae, the viral RNAs of which are transcribed in the cell nucleus as bona fide cellular mRNAs, endowed with a 5’ cap (7-methylguanylate, m7G) and a 3’ poly A tail.

How can this enzyme distinguish between cellular and viral RNAs? One possible hypothesis would be that ISG20 is capable of discriminating RNAs based on specific features present, absent, or differentially present in one versus the other RNA species, as, for example, epitranscriptomic modifications, 5’ cap, or poly A tails. However, while some of the viruses targeted by ISG20 lack some of these canonical features present on cellular RNAs, other viruses do possess them (Table 1). As such, the exact mechanism through which ISG20 identifies its RNA targets remains unclear.

At present, the results obtained and confirmed by numerous laboratories concur in three experimental evidences: ISG20 behaves as a potent RNase in vitro; this enzyme inhibits the replication of numerous viruses and its enzymatic activity is key for this property, given that a single point mutation that disrupts the catalytic site of ISG20 both abolishes its ability to degrade RNA in vitro and impairs its antiviral behavior. The explanation of how this behavior underlines the antiviral mechanism of action of ISG20 is still a matter of debate, and currently, four models have been proposed: two in which ISG20 directly degrades its viral target and two in which ISG20 blocks the translation from viral RNA without degrading them. Given that the RNase activity of ISG20 remains nonetheless important for this translational block, it follows that ISG20 must target a cellular RNA, whose identity remains, however, unknown.

**Mechanism 1: direct viral RNA degradation**

The first model proposed on the basis of the experimental evidence described above was that ISG20 directly degraded viral RNA [30,36,37,48,49] (Fig. 3). Indeed, the expression of ISG20 led to lower accumulation of viral RNA and synthetic viral RNA mimics were also efficiently degraded in vitro.

In addition to the fact that the direct binding of WT ISG20 to viral RNA has not been formally demonstrated in cells, the major caveat of this model is that it fails to provide the basis through which ISG20 can distinguish viral from cellular RNA substrates. Indeed, ISG20 is capable of degrading most ssRNA in vitro [10,29], not just viral substrates so that the question of how ISG20 spares cellular RNAs remains unaddressed. At present, a single study reported the specific binding of ISG20 to the adenosine-methylated (m6A, adenosine in position 1907) form of the HBV RNA (e), a particular stem–loop structure and unique site for m6A modification on the HBV transcripts (or two sites within two identical e in 5’ or 3’ ends for the pregenomic RNA) [50]. However, the association between ISG20 and this methylated...
structure was mediated through a direct protein–protein interaction with the m6A reader YTH-domain family 2 (YTHDF2). Given the extent of the m6A modifications on cellular mRNAs [51], it is difficult to envision how YTHDF2 binding, alone, could help ISG20 discriminate between cellular and viral mRNAs. However, this finding is of interest because it raises the possibility that ISG20 connects with the complex epitranscriptomic machinery, perhaps in combination with other RNA features as, for instance, the polyA tail or the 5' cap. The heterogeneous modifications and variable presence of these modifications among the large panel of viruses targeted by ISG20 do not allow for the moment the identification of a unique feature driving susceptibility or resistance to ISG20.

**Mechanism number 2. Direct degradation of deaminated viral DNA**

While the activity of ISG20 on ssDNA is generally lower when compared to ssRNA in vitro, a recent study indicated that it could be increased in the presence of deoxyuridines (dU) [35]. In so doing, the authors of the study proposed an interesting model of cooperativity between two cellular antiviral factors against HBV, connecting the cytosine deamination activity of the apolipoprotein B mRNA-editing enzyme catalytic subunit 3A (APOBEC3A) to the ensuing degradative activity of ISG20.

Members of the APOBEC3 family (A through H in humans) are prototype antiviral factors well studied in the context of retroviral infection [52,53]. In this case, APOBEC3s are incorporated into virion particles and act during the process of reverse transcription in the cytoplasm of target cells by deaminating cytosines in the first strand of reverse-transcribed viral DNA (the negative-strand). As a result, deaminated C > U sites are misread when this strand is used as a template for the synthesis of the second strand (the positive-strand) resulting in G-to-A mutations along the viral genome. For this family of viruses, the extent of accumulation of deleterious mutations along the viral genome (stop codons, mutations with negative effect on the protein functionality, etc.) can be so considerable that viral replication is severely impaired in a mechanism that has been referred to as death by mutagenesis [53,54].

The mechanism of cytosine deamination described here in the case of HBV is distinct from the one of Retroviridae: first because it occurs in the nucleus and is carried out by APOBEC3A, which is together with APOBEC3B, the sole nuclear APOBEC3 member; and second, because it is carried out on double-stranded covalently closed circular DNA (cccDNA) [55]. Its outcome is therefore not the introduction of mutations in the genome of the virus but the degradation of the viral DNA by ISG20.

---

**Fig. 3.** Proposed mechanisms of viral inhibition by ISG20. The figure presents the four models of action that have been ascribed to ISG20. From left to right, in the first two models ISG20 has been proposed to directly degrade viral nucleic acid in its RNA or deaminated DNA forms (models 1 and 2, respectively). In models 3 and 4, ISG20 has been proposed to inhibit viral translation but not to promote direct viral RNA degradation. In model 3, translation inhibition is promoted through an unknown mechanism by ISG20 by the induction of IFN and more specifically of IFIT1, a well-known translation inhibitor that targets viral RNAs devoid of a proper 5’ cap. In model 4, translation inhibition occurs independently from IFN induction and results in a defect in translation efficiency, likely due to the direct modification of the translation machinery. Also, in this case, the identity of the targeted RNAs remains unknown.
in the viral genome, but rather the stamping of viral DNA for ISG20-mediated degradation [35]. Given that APOBEC3 proteins require a single-strand DNA intermediate to act [56,57], it is likely that APOBEC3A acts on transcriptionally active cccDNA in which the transcription machinery opens up the double-stranded DNA (Fig. 3).

As said before, this mechanism of action is of interest because it models the concerted action of two antiviral factors. Several questions remain, however, unaddressed around the specificity of action of ISG20. First, the major enzymatic functions of ISG20 are directed against RNA, and second, most DNA viruses do replicate in the nucleus, but for the most part seem resistant to ISG20 [37,39]. It will be therefore important to understand how these viruses avoid the combined action of APOBEC3A-ISG20. The restricted pattern of expression of APOBEC3 to cells of the myeloid lineage could provide a first line of specificity to the action of ISG20 [58], but certainly cannot explain it alone. Third and more importantly, the cellular genome is constantly exposed to spontaneous deamination [59,60]. It will be thus imperative to determine how the cellular genome protects itself from ISG20.

**Mechanism 3: IFN induction and IFIT1-mediated translation inhibition of viral RNA**

For most highly replicating RNA viruses, the first round of translation of viral proteins is capital to ensure viral RNA amplification. As such, an alternative explanation for the lower accumulation of viral RNA observed in numerous studies in the presence of ISG20 could be an inhibitory effect of the first round of viral translation, which would severely undermine the extent of viral RNA amplification.

Translation inhibition has been reported in mouse embryonic fibroblasts (MEF) overexpressing the murine ISG20 (mISG20) that shares 82% identity with human ISG20 (Fig. 3). In this study and in agreement with other studies, the authors found that ISG20-mediated inhibition of the chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) did not involve the degradation of viral RNAs, but rather the inhibition of translation of viral proteins [12]. Interestingly, translation inhibition was indirectly due to the stimulation of IFN-I responses and more specifically to the expression of the interferon-induced protein with tetratricopeptide 1 (IFIT1), a well-known translation suppressor protein that targets uncapped viral RNAs [12,61,62]. In this model therefore, ISG20 inhibits viral translation indirectly through the induction of an IFN response and IFIT1. Despite the fact that a later study failed to confirm IFN and IFIT1 induction by ISG20 [39], this study opens up the possibility that ISG20 can drive larger responses besides direct viral inhibition.

This model leaves for the moment unanswered two major questions. First, ISG20 is itself an IFN-regulated protein so that its reported induction of IFN would necessarily occur in an environment already primed by IFN. As such, either ISG20 acts as a positive regulator to potentiate or sustain IFN responses over time (perhaps by processing viral RNAs as RNAseL), or this mechanism is restricted to cell types in which ISG20 expression is induced by other signals, as, for example, estrogens. Second, this model does not explain the broad mechanism of viral inhibition of ISG20, as the spectrum of viruses inhibited by ISG20 is larger than those targeted by IFIT1 and it extends to viruses with a cellular-like m7G-5’ cap. Importantly, given that the exonuclease activity of ISG20 is important for this behavior, the identity of the RNAs (cellular or viral) targeted by ISG20 to induce IFN responses remains to be identified.

**Mechanism 4: Translation inhibition of nonself RNAs in the absence of IFN induction.** This mechanism was proposed recently by our laboratory following experimental observations that ISG20 exerted a strong impairment in the translation of viral proteins following VSV infection in spite of a very mild decrease in viral RNAs (Fig. 3) and in the absence of IFN-I or IFIT1 induction [39].

Interestingly, a similar behavior could be reproduced upon ectopic transfection of plasmid DNAs independently from the nature of the reporter gene examined (i.e., cellular or viral, spliced or unspliced). On the contrary, ISG20 had no effect when this exact reporter cassette was stably integrated into the host genome.

Translation inhibition was independent from initiation factors as it affected equally reporter genes under the control of the cricket paralysis virus (CrPV) 5’-untranslated region that drives initiation of factorless translation [63]. Interestingly, the suppressive effects of ISG20 were accompanied by its partial recruitment to cytoplasmic processing bodies (P bodies), important and dynamic sites of RNA metabolism [64], although it was not possible to determine whether this association was causal or secondary to the translational block itself [39].

VSV infection and transient DNA transfection do not share many features in common. However, they both represent the massive flooding of the cell with nonself genetic material, and in both cases, the process
of cellular translation is largely redirected toward a single (in the case of ectopic DNA transfection) or a narrow set (in the case of viral infection) of RNA transcripts, a situation that is unusual for the cell and often associated with viral infection.

Given the absence of target RNA degradation, but in light of the importance of an intact RNase activity, we proposed that ISG20 could affect cellular translation by degrading a cellular RNA substrate, which affects proportionally the most actively translated RNAs, working as a threshold translational controller.

This model is of interest because it is relatively independent from a single RNA feature. However, it can be influenced by all of them and in particular by the extent of epitranscriptomic modifications that are added cotranscriptionally and thus depend on the chromatin status of the target gene.

In this respect, rRNAs and small nucleolar RNAs (rRNAs and snoRNAs, respectively) represent interesting potential targets with which ISG20 could alter the overall translational abilities of the cell. snoRNAs are small nonprotein coding RNAs (60–300 nt) involved in a number of physiological processes among the post-translational modification of rRNAs, process in which they guide the methylase fibrillarin on specific sites of rRNAs promoting 2′-O-methylation modifications [65, 66]. The weight of these modifications in the activity of ribosomes remains to be fully apprehended. However, an increasing number of reports support the notion that specialized subsets of ribosomes are formed in response to certain stimuli [67–69], and in this context, ISG20 could promote the formation of specialized pools of ribosomes, thus influencing the translational capacity of the cell.

This model would accommodate inhibition of a broad spectrum of viruses targeted by ISG20 according to a single mechanism of action. However, also in this case the identity of the RNAs targeted by ISG20 remains unidentified.

Open question 1: the intracellular whereabouts of ISG20

The intracellular distribution of ISG20 has not been the subject of intense studies so far. Its small size (around 20 kDa) allows it to be fairly well distributed in both cell cytoplasm and nucleus. A subtler localization of ISG20 has been described upon strong detergent permeabilization in promyelocytic leukemia (PML) bodies, nucleolus, and Cajal bodies [70]. PML bodies are involved in several physiological processes including antiviral responses, and they are often disrupted by viral infection [71–73]. Instead, nucleolus and CB are sites of formation and processing of rRNA and small nuclear ribonucleoproteins (snRNPs). An extensive literature exists on these discrete nuclear bodies, and the reader is invited to read some of the following reviews [74–78]. In light of the association of a fraction of ISG20 with these structures, it is thus possible that ISG20 is involved in small nuclear RNA (snRNA) and rRNA biogenesis and/or maturation [70], although this would support an indirect mechanism of viral inhibition by ISG20, rather than a direct one.

In the case of translation inhibition, our laboratory also reported that a fraction of cytoplasmic ISG20 could migrate (or induce) processing bodies (P bodies), which are cytoplasmic membraneless compartments involved in RNA decay and/or control of translation by RNA storage [39, 79], in line with their effect in translation inhibition.

However, the dynamics of ISG20 and an extensive characterization of its intracellular distribution during homeostasis or during the context of infection are crucially lacking and this may yield important clues as to the mechanisms of inhibition of ISG20. For instance, with few exceptions [39], a single mutant is often used in several studies (D94, or similar mutations in the DEDD residues), but the use of additional mutants could extend our comprehension of the links between cellular localization of ISG20 and its antiviral activities. Similarly, although ISG20 is distributed in both cell cytoplasm and nucleus it is unclear whether trafficking between one and the other location is important for the antiviral activity. Certainly, this will be an interesting area of investigation for future studies.

Open question 2: the specificity determinants of ISG20

While a large number of viruses are susceptible to the action of ISG20, several remain resistant to it. This includes not only DNA viruses such as adenoviruses or the Epstein–Barr virus but also RNA viruses such as several, although not all, members of Phenuiviridae [80], as well as SARS-CoV [24], in vitro -driven evolution toward resistance to ISG20 in Bunyamwera orthobunyavirus (BUNV), prototype virus of Peribunyaviridae family, has led to interesting hints about the determinants that may modulate susceptibility and resistance to this restriction factors [80]. Several mutations were indeed identified in BUNVs that adapted to replicate in the presence of ISG20 expression. These mutations occurred in the three segments of the viral genome (short (S), large (L), and medium (M)). Despite the fact that mutations in the different genome
segments exhibited unequal contributions to the extent of viral replication likely due to their respective roles in this process, adaptive mutations were observed in potential structural RNA elements (mutations outside open reading frames, ORFs), as well as in the N and NSs proteins. Although the relative contribution of these mutations to ISG20 resistance has not been further dissected, these results indicate that both RNA-binding proteins as the viral N protein and cis-acting elements on the viral RNA may influence susceptibility to ISG20.

Viral proteins may indeed, as cellular proteins, shield viral RNAs from the degradative action of ISG20, and similarly, particular stem–loop structures may also protect RNA, as ISG20 displays no reported activity against double-stranded RNA. In this respect, the RNA of bunyaviruses is not polyadenylated, but contains a conserved 3’ stem–loop structure that may be important to mediate the resistance of some, although not all, members of this viral order.

In addition to the already-mentioned 5’-cap and poly(A) tail in the 3’ end, cellular mRNAs are also heavily modified either cotranscriptionally or shortly after transcription by the addition of the following modifications: ribose 2’-O-methylation, pseudouridine, inosine, m1A, and 5-methylcytosine (Fig. 4). Collectively, these dynamic modifications are referred to as epitranscriptomic modifications and are involved in all aspects of the RNA biology, such as stability or efficiency of translation [81,82], aspects that they influence either directly or indirectly through the recruitment of a large number of cellular proteins [83,84]. Readers are invited to read the following reviews for a more complete overview of epitranscriptomic modifications [84–88].

These modifications are mentioned here because an increasing number of reports indicate that viruses themselves can hijack these processes to their advantage to modulate the metabolism of their own RNAs, in addition to negative impact cellular defenses [89–91]. It is for the moment unclear whether the activity of ISG20 can be altered by the variety or the abundance of specific epitranscriptomic marks, because exhaustive studies of all these modifications in the context of specific viruses are lacking (Table 1).

However, we can hypothesize that the extent and or abundance of epitranscriptomic marks in a given RNA could modulate either directly or indirectly through...

![Fig. 4. Features expected to modulate RNA susceptibility to ISG20.](image)

Intrinsic features of the RNA as poly A tail or secondary structures, as well as epitranscriptomic modifications that may in principle affect susceptibility to ISG20. The RNA-binding proteins that can dock on the RNA as a consequence of these modifications are not shown for simplicity. m6A: N6-methyladenosine, m5C: 5-methylcytosine, m7G: N7-methylguanosine, l: inosine, ψ: pseudouridine, m1A: N1-methyladenosine.
RNA-binding proteins the action of ISG20. The weight of these modifications in the antiviral functions of ISG20 can be direct, for instance, by providing protection from direct viral RNA degradation, or indirect, for example, by altering the efficiency of translation by specialized subsets of ribosomes, as proposed in the translation inhibition models.

**Concluding remarks**

Overall, several studies indicate that ISG20 is an important and broad antiviral effector during innate immune responses. While the exonuclease activity of ISG20 is deemed necessary for its antiviral activity toward multiple viruses, the identity of the nucleic acids targeted by ISG20 remains unclear, ranging from viral RNA to deaminated single-stranded DNA or to cellular RNA targets that may influence translation. Rarely mentioned, high levels of ISG20 expression lead to cell death [39,92] and it is at present unknown whether regulatory mechanisms exist that keep in check this deleterious effect. In addition to highlighting the importance of carefully controlling ISG20 expression levels during viral replication studies, these results indicate that the specificity of ISG20 for its viral targets is not absolute. Indeed, under certain circumstances the cell can also be susceptible to ISG20, stressing all the more the need to identify the RNA features that govern susceptibility to this factor.

Despite the fact that the underlying molecular mechanism leading to viral inhibition remains to be defined precisely, ISG20 has shown potential for use as broad antiviral inhibitor after vehiculation inside the cell as fusion protein with antibodies (Fc fragment) or with Tat cell-penetrating peptides [93,94]. In addition, ISG20 expression has been also associated with glioma and radioresistance in oral cancer cells and other types of cancer [18,48,95]. As such, the molecular definition of its mechanism of action in the cell could spur novel developments in antiviral treatment and yield clues to other cellular processes of broader interest. Future studies will certainly shed new light on several key aspects of the biology of ISG20.

**Acknowledgments**

Work on ISG20, as well as the PhD fellowship of SD, is supported by a grant from the French Agence Nationale de la Recherche (project ANR-20-CE15-0025-01). AC is a permanent researcher of the Centre Nationale de la Recherche Scientifique (CNRS).

**Conflict of interest**

The authors have declared that there is no conflict of interest.

**Author contribution**

SD, CL, FF, and AC conceived and wrote the manuscript.

**References**

1. Isaacs A, Lindenmann J. Virus interference: I. The interferon. By Alick Isaacs and Jean Lindenmann, 1957. *CA Cancer J Clin.* 1957;38:280–90.
2. Schoggins JW. Interferon-stimulated genes: what do they all do? *Annu Rev Virol.* 2019;6:567–84.
3. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. *Nat Rev Immunol.* 2015;15:87–103.
4. Manry J, Laval G, Patin E, Fornarino S, Itan Y, Fumagalli M, et al. Evolutionary genetic dissection of human interferons. *J Exp Med.* 2011;208:2747–59.
5. Capobianchi MR, Uleri E, Caglioti C, Dolei A. Type I IFN family members: Similarity, differences and interaction. *Cytokine Growth Factor Rev.* 2015;26:103–11.
6. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. *Nat Rev Immunol.* 2008;8:559–68.
7. Gongora C, David G, Pintard L, Tissot C, Hua TD, Dejean A, et al. Molecular cloning of a new interferon-induced PML nuclear body-associated protein. *J Biol Chem.* 1997;272:19457–63.
8. Pentecost BT. Expression and estrogen regulation of the HEM45 mRNA in human tumor lines and in the rat uterus. *J Steroid Biochem Mol Biol.* 1998;64:25–33.
9. Li X-L, Blackford JA, Hassel BA. RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection. *J Virol.* 1998;72:2752–9.
10. Nguyen LH, Espert L, Mechti N, Wilson DM. The human interferon- and estrogen-regulated ISG20/HEM45 Gene product degrades single-stranded RNA and DNA in Vitro. *Biochemistry.* 2001;40:7174–9.
11. Gongora C, Degols G, Espert L, Hua TD, Mechti N. A unique ISRE, in the TATA-less human Isg20 promoter, confers IRF-1-mediated responsiveness to both interferon type I and type II. *Nucleic Acids Res.* 2000;28:2333–41.
12. Weiss CM, Trobaugh DW, Sun C, Lucas TM, Diamond MS, Ryman KD, et al. The interferon-induced exonuclease ISG20 exerts antiviral activity through upregulation of type I interferon response proteins. *mSphere.* 2018;3:18.
The ISG20 RNase in antiviral responses

13 Imaizumi T, Mechti N, Matsumiya T, Sakaki H, Kubota K, Yoshida H, et al. Expression of interferon-stimulated gene 20 in vascular endothelial cells. Microbiol Immunol. 2008;52:30–5.
14 Wang J, Wang Y, Xing P, Liu Q, Zhang C, Sui Y, et al. Development and validation of a hypoxia-related prognostic signature for breast cancer. Oncol Lett. 2020;20:1906–14.
15 Alsheikh HAM, Metge BJ, Pruitt HC, Kammerud SC, Chen D, Wei S, et al. Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors. Oncogenesis. 2021;10:45.
16 Qu X, Shi Z, Guo J, Guo C, Qiu J, Hua K. Identification of a novel six-gene signature with potential prognostic and therapeutic value in cervical cancer. Cancer Med. 2021;10:6881–96.
17 Yu J, Liu T-T, Liang L-L, Liu J, Cai H-Q, Zeng J, et al. Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer. Cancer Cell Int. 2021;21:133.
18 Miyashita H, Fukimoto M, Kuwahara Y, Takahashi T, Fukimoto M. ISG20 is overexpressed in clinically relevant radioresistant oral cancer cells. Int J Clin Exp Pathol. 2020;13:1633–9.
19 Xu T, Ruan H, Gao S, Liu J, Liu Y, Song Z, et al. ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma. Aging. 2020;12:1808–27.
20 Lin S-L, Wu S-M, Chung I-H, Lin Y-H, Chen C-Y, Chi H-C, et al. Stimulation of interferon-stimulated gene 20 by thyroid hormone enhances angiogenesis in liver cancer. Neoplasia. 2018;20:57–68.
21 Van Tong H, Hoan NX, Binh MT, Quyen DT, Meyer CG, Song LH, et al. Interferon-stimulated gene 20 kDa protein serum levels and clinical outcome of hepatitis B virus-related liver diseases. Oncotarget. 2018;9:27858–71.
22 Lee J-H, Koh YA, Cho C-K, Lee S-J, Lee Y-S, Bae S. Identification of a novel ionizing radiation-induced nuclease, AEN, and its functional characterization in apoptosis. Biochem Biophys Res Comm. 2005;337:39–47.
23 Couté Y, Kindbeiter K, Belin S, Dieckmann R, Duret L, Bezin L, et al. ISG20L2, a novel vertebrate nucleolar exonuclease involved in ribosome biogenesis. Mol Cell Proteomics. 2008;7:546–59.
24 Zhou Z, Wang N, Woodson SE, Dong Q, Wang J, Liang Y, et al. Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology. 2011;409:175–88.
25 Shevelev IV, Hübscher U. The 3′–5′ exonucleases. Nat Rev Mol Cell Biol. 2002;3:364–76.
26 Mason PA, Cox LS. The role of DNA exonucleases in protecting genome stability and their impact on ageing. AGE. 2012;34:1317–40.
27 Zuo Y. Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. Nucleic Acids Res. 2001;29:1017–26.
28 Viswanathan M, Lovett ST. Exonuclease X of Escherichia coli. J Biol Chem. 1999;274:30094–100.
29 Horio T, Murai M, Inoue T, Hamasaki T, Tanaka T, Ohgi T. Crystal structure of human ISG20, an interferon-induced antiviral ribonuclease. FEBS Lett. 2004;577:111–6.
30 Liu Y, Nie H, Mao R, Mitra B, Cai D, Yan R, et al. Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog. 2017;13:e1006296.
31 Beck J. Hepatitis B virus replication. WJG. 2007;13:48.
32 Kramvis A, Kew MC. Structure and function of the encapsidation signal of hepatitis B virus. J Viral Hepat. 1998;5:357–67.
33 Flodell S. The apical stem-loop of the hepatitis B virus encapsidation signal folds into a stable tri-loop with two underlying pyrimidine bulges. Nucleic Acids Res. 2002;30:4803–11.
34 LeBlanc RM, Kasprzak WK, Longhini AP, O lenginski LT, Abulwerdi F, Ginocchio S, et al. Structural insights of the conserved “priming loop” of hepatitis B virus pre-genomic RNA. J Biomol Struct Dyn. 2021;44:1–13.
35 Stadler D, Kächele M, Jones AN, Hess J, Urban C, Schneider J, et al. (Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep. 2021;22:68.
36 Esprt L, Degols G, Lin Y-L, Vincent T, Benkirane M, Mechti N. Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J Gen Virol. 2005;86:2221–9.
37 Esprt L, Degols G, Gongora C, Blondel D, Williams BR, Silverman RH, et al. ISG20, a new interferon-induced rmase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem. 2003;278:16151–8.
38 Jiang D, Weidner JM, Qing M, Pan X-B, Guo H, Xu C, et al. Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol. 2010;84:8332–41.
39 Wu N, Nguyen X-N, Wang L, Appourchaux R, Zhang C, Panthu B, et al. The interferon stimulated gene 20 protein (ISG20) is an innate defense antiviral factor that discriminates self versus non-self translation. PLoS Pathog. 2019;15:e1008093.
40 Hu J, Seeger C. Hepadnavirus genome replication and persistence. Cold Spring Harb Perspect Med. 2015;5:a021386.
41 Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.
The ISG20 RNase in antiviral responses

S. Deymier et al.

42 Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard J-M. The Complementary Strand of the Human T-Cell Leukemia Virus Type 1 RNA Genome Encodes a bZIP Transcription Factor That Down-Regulates Viral Transcription. *J Virol*. 2002;76:12813–22.

43 Savorot J, Mesnard J-M, Gross A, Chazal N. Antisense transcripts and antisense protein: a new perspective on human immunodeficiency virus type 1. *Front Microbiol*. 2021;11:625941.

44 Blondel D, Maarifi G, Nisole S, Chelbi-Alix M. Resistance to rhabdoviridae infection and subversion of antiviral responses. *Virology*. 2015;7:3675–702.

45 Guu TSY, Zheng W, Tao YJ. Bunyavirus: Structure and Replication. In: Rossmann MG, Rao VB, editors. *Viral Molecular Machines*. US, Boston, MA: Springer; 2012. p. 245–66.

46 Sun X, Li D, Wang Z, Liu Q, Wei Y, Liu T. A dimorphism shift of hepatitis B virus capsids in response to ionic conditions. *Nanoscale*. 2018;10:16984–9.

47 Couch RB. Orthomyxoviruses. In: Baron S, editors. *Medical Microbiology*. 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.

48 Zheng Z, Wang L, Pan J. Interferon-stimulated gene 20-kDa protein (ISG20) in infection and disease: Review and outlook. *Intractable Rare Dis Res*. 2017;6:35–40.

49 Leong CR, Funami K, Oshiumi H, Mengao D, Takaki H, Matsumoto M, et al. Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo. *Oncotarget*. 2016;7:68179–93.

50 Imam H, Khan M, Gokhale NS, McIntyre ABR, Kim G-W, Jang JY, et al. N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle. *Proc Natl Acad Sci USA*. 2018;115:8829–34.

51 Shi H, Wei J, He C. Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. *Mol Cell*. 2019;74:640–50.

52 Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. *Phil Trans R Soc B*. 2009;364:675–87.

53 Harris RS, Dudley JP. APOBECs and virus restriction. *Virology*. 2015;479–480:131–45.

54 Vartanian J-P, Sommer P, Wain-Hobson S. Death and the retrovirus. *Trends Mol Med*. 2003;9:409–13.

55 Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. *Nat Struct Mol Biol*. 2010;17:222–9.
and is associated with nuclear SMN protein-containing complexes. J Cell Biochem. 2006;98:1320–33.
71 Kelly C, Van Driel R, Wilkinson GWG. Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. J Gen Virol. 1995;76:2887–93.
72 Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene. 2001;20:7274–86.
73 Everett RD, Chelbi-Alix MK. PML and PML nuclear bodies: Implications in antiviral defence. Biochimie. 2007;89:819–30.
74 Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8:1006–16.
75 Dandri M, Misteli T. Biogenesis of Nuclear Bodies. Cold Spring Harbor Perspect Biol. 2010;2:a000711.
76 Mao YS, Zhang B, Spector DL. Biogenesis and function of nuclear bodies. Trends Genet. 2011;27:295–306.
77 Couchaine EM, Lu A, Neugebauer KM. Droplet organelles? EMBO J. 2016;35:1603–12.
78 Trinkle-Mulcahy L, Sleeman JE. The Cajal body and the nucleolus: “In a relationship” or “It’s complicated”? RNA Biol. 2017;14:739–51. https://doi.org/10.1080/15476286.2016.1236169
79 Decker CJ, Parker R. P-bodies and stress granules: possible roles in the control of translation and mRNA degradation. Cold Spring Harbor Perspect Biol. 2012;4: a012286.
80 Feng J, Wickenhagen A, Turnbull ML, Rezelj VV, Kreher F, Tilston-Lunel NL, et al. Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20. J Virol. 2018;92: e02140–17.
81 Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m 6 A RNA methylation. Nat Rev Genet. 2014;15:293–306.
82 Frye M, Harada BT, Behm M, He C. RNA modifications modulate gene expression during development. Science. 2018;361:1346–9.
83 Yang Y, Hsu PJ, Chen Y-S, Yang Y-G. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616–24. https://doi.org/10.1038/s41422-018-0040-8
84 Wiener D, Schwartz S. The epitranscriptome beyond m6A. Nat Rev Genet. 2021;22:119–31.
85 Wang X, He C. Dynamic RNA Modifications in Posttranscriptional Regulation. Mol Cell. 2014;56:5–12.
86 Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38:182–93. https://doi.org/10.1016/j.tig.2021.06.014
87 Harcourt EM, Kietrys AM, Kool ET. Chemical and structural effects of base modifications in messenger RNA. Nature. 2017;541:339–46.
88 Boo SH, Kim YK. The emerging role of RNA modifications in the regulation of mRNA stability. Exp Mol Med. 2020;52:400–8.
89 Netzband R, Pager CT. Epitranscriptomic marks: Emerging modulators of RNA virus gene expression. WIREs RNA. 2020;11. https://doi.org/10.1002/wrna.1576
90 Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, et al. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature. 2010;468:452–6.
91 Tsai K, Cullen BR. Epigenetic and epitranscriptomic regulation of viral replication. Nat Rev Microbiol. 2020;18:559–70.
92 Degols G, Eldin P, Mechi N. ISG20, an actor of the innate immune response. Biochimie. 2007;89:831–5.
93 Ding J, Aldo P, Roberts CM, Stabach P, Liu H, You Y, et al. Placenta-derived interferon-stimulated gene 20 controls ZIKV virus infection. EMBO Rep. 2021;22:2450.
94 Liu K, Li Y, Zhou B, Wang F, Huan B, Shao D, et al. A conjugate protein containing HIV TAT, ISG20, and a PRRSV polymerase binding inhibits PRRSV replication and may be a novel therapeutic platform. Rev Vet Sci. 2017;113:13–20.
95 Gao M, Lin Y, Liu X, Li Y, Zhang C, Wang Z, et al. ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. OncoImmunology. 2019;8:e1354038.
96 Qu H, Li J, Yang L, Sun L, Liu W, He H. Influenza A Virus-induced expression of ISG20 inhibits viral replication by interacting with nucleoprotein. Virus Genes. 2016;52:759–67.
97 Krug RM, Morgan MA, Shatkin AJ. Influenza viral mRNA contains internal N6-methyladenosine and 5′-terminal 7-methylguanosine in cap structures. J Virol. 1976;20:45–53.
98 Courtney DG, Kennedy EM, Dumm RE, Bogerd HP, Tsai K, Heaton NS, et al. Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication. Cell Host Microbe. 2017;22:377–386.e5.
99 Olschewski S, Cusack S, Rosenthal M. The Cap-Snatching Mechanism of Bunyaviruses. Trends Microbiol. 2020;28:293–303.
100 Dunn EF, Pritlove DC, Elliott RM. The S RNA genome segments of Batai, Cache Valley, Guaroa, Kairi, Lumbo, Main Drain and Northway bunyaviruses: sequence determination and analysis. J Gen Virol. 1994;75:597–608.
101 Wang JT, McElvain LE, Whelan SPJ. Vesicular Stomatitis Virus mRNA Capping Machinery Requires
Specific cis-Acting Signals in the RNA. *J Virol.* 2007;81:11499–506.

102 Qiu W, Zhang Q, Zhang R, Lu Y, Wang X, Tian H, et al. N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA. *Nat Commun.* 2021;12:1582.

103 Hwang LN, Englund N, Pattnaik AK. Polyadenylation of Vesicular Stomatitis Virus mRNA Dictates Efficient Transcription Termination at the Intercistronic Gene Junctions. *J Virol.* 1998;72:1805–13.

104 Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. *J Virol.* 2008;82:1665–78.

105 Jia Y, Wei L, Jiang D, Cong X, Fei R. Investigating the inhibitory effects of interferon-alpha on the replication of hepatitis C virus replicon. *Zhonghua Yi Xue Za Zhi.* 2005;85:2065–9.

106 Bradrick SS. The hepatitis C virus 3'-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase. *Nucleic Acids Res.* 2006;34:1293–303.

107 Moes L, Wirth M. The internal initiation of translation in bovine viral diarrhea virus RNA depends on the presence of an RNA pseudoknot upstream of the initiation codon. *Virol J.* 2007;4:124.

108 McIntyre W, Netzband R, Bonenfant G, Biegel JM, Miller C, Fuchs G, et al. Positive-sense RNA viruses reveal the complexity and dynamics of the cellular and viral epitranscriptomes during infection. *Nucleic Acids Res.* 2018;46:5776–91.

109 Kolykhlov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *J Virol.* 1996;70:3363–71.

110 Collett MS, Anderson DK, Retzel E. Comparisons of the pestivirus bovine viral diarrhea virus with members of the flaviviridae. *J Gen Virol.* 1988;69:2637–43.

111 Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, et al. Structure and Function of Flavivirus NS5 Methyltransferase. *J Virol.* 2007;81:3891–903.

112 Dong H, Ren S, Zhang B, Zhou Y, Puig-Basagoiti F, Li H, et al. West nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. *J Virol.* 2008;82:4295–307.

113 Saeedi BJ, Geiss BJ. Regulation of flavivirus RNA synthesis and capping: Regulation of flavivirus RNA synthesis and capping. *Wires RNA.* 2013;4:723–35.

114 Song Y, Mugavero J, Stauff CB, Wimmer E, Dengue and Zika Virus 3' Untranslated Regions Harbor Internal Ribosomal Entry Site Functions. *MBio.* 2019;10:19.

115 Gokhale NS, McIntyre ABR, McFadden MJ, Roder AE, Kennedy EM, Gandara JA, et al. N6-methyladenosine in flaviviridae viral RNA genomes regulates infection. *Cell Host & Microbe.* 2016;20:654–65. https://doi.org/10.1016/j.chom.2016.09.015

116 Bergamini G, Preiss T, Hentze MW. Picornavirus IRESes and the poly(A) tail jointly promote cap-independent translation in a mammalian cell-free system. *RNA.* 2000;6:1781–90.

117 Jang SK, Pestova TV, Hellen CUT, Witherell GW, Wimmer E. Cap-Independent Translation of Picornavirus RN As: Structure and Function of the Internal Ribosomal Entry Site. *Enzyme.* 1990;44:292–309.

118 Decroly E, Ferron F, Lescar J, Canard B. Conventional and unconventional mechanisms for capping viral mRNA. *Nat Rev Microbiol.* 2012;10:51–65.

119 Zhang Y, Burke CW, Ryman KD, Klimstra WB. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. *J Virol.* 2007;81:11246–55.

120 Hyde JL, Diamond MS. Innate immune restriction and antagonism of viral RNA lacking 2-O methylation. *Virology.* 2015;479–480:66–74.

121 Hsuchen C-C, Dubin DT. Di- and trimethylated congeners of 7-methylguanine in Sindbis virus mRNA. *Nature.* 1976;264:190–1.

122 Furutani Y, Toguchi M, Higuchi S, Yanaka K, Gailhouste L, Qin X-Y, et al. Establishment of a Rapid Detection System for ISG20-Dependent SARS-CoV-2 Subreplicon RNA Degradation Induced by Interferon-α. *IJMS.* 2021;22:11641.

123 Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. *Advances in Virus Research.* Amsterdam: Elsevier; 2016. p. 165–92.

124 Kim D, Lee J-Y, Yang J-S, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. *Cell.* 2020;181:914–921.e10.

125 Liu J, Xu Y-P, Li K, Ye Q, Zhou H-Y, Sun H, et al. The m6A methylome of SARS-CoV-2 in host cells. *Cell Research.* 2021;31:404–14. https://doi.org/10.1038/s41422-020-00465-7

126 Zahoor MA, Xue G, Sato H, Murakami T, Takeshima S, Aida Y. HIV-1 Vpr induces interferon-stimulated genes in human monocyte-derived macrophages. *PLoS One.* 2014;9:e106418.

127 Zahoor MA, Xue G, Sato H, Aida Y. Genome-wide transcriptional profiling reveals that HIV-1 Vpr differentially regulates interferon-stimulated genes in human monocyte-derived dendritic cells. *Virus Res.* 2015;208:156–63.
128 Wilusz J. Putting an ‘End’ to HIV mRNAs: capping and polyadenylation as potential therapeutic targets. *AIDS Res Ther*. 2013;10:31.
129 Yedavalli VSRK, Jeang K-T. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs. *Proc Natl Acad Sci*. 2010;107:14787–92.
130 Courtney DG. Post-Transcriptional Regulation of Viral RNA through Epitranscriptional Modification. *Cells*. 2021;10:1129.
131 Doria-Rose NA, Klein RM, Manion MM, O’Dell S, Phogat A, Chakrabarti B, et al. Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross Neutralizing Antibodies. *J Virol*. 2009;83:188–99.
132 Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. *Proc Natl Acad Sci*. 2004;101:6669–74.
133 Imam H, Kim G-W, Mir SA, Khan M, Siddiqui A. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts. *PLoS Pathog*. 2020;16:e1008338.
134 Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. *Virology*. 2015;479–480:672–86.
135 Block TM, Young JAT, Javanbakht H, Sofia MJ, Zhou T. Host RNA quality control as a hepatitis B antiviral target. *Antiviral Res*. 2021;186:104972.